Kuros Biosciences AG

Kuros reports 149% increase in direct MagnetOs sales and exceeds cash flow breakeven in the first nine months of 2024

Kuros Biosciences Reports First Half of 2024 Results

Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales

Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023

Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA

Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management